The Progressive Fibrosing Interstitial Lung Disease (PF-ILD) market is currently valued at USD 4,742.2 Million in 2023 and is ...

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

Find out how this could enhance access to quality healthcare, with an emphasis on mental health services for vulnerable populations.

Unitronix's Continued Investment in Blockchain Innovations Now Influencing Political Engagement, Campaign Funding, and Decentralized Governance. For investor and general information, please email ...

*Based on data released by the Federal Election Commission on October 01, 2024 except for independent expenditure and communication cost, contributions to federal candidates, and contributions from ...

The Angelika Amon research building is named after a Viennese pioneer in cell biology who was closely connected with Boehringer Ingelheim. Image credit: Boehringer Ingelheim. Boehringer Ingelheim has ...

Clinical trial results shared by Boehringer Ingelheim and Insilico Medicine showed improvement in idiopathic pulmonary fibrosis, an intractable lung disease for which current treatment options fail to ...

By Noah Weiland and Rebecca Robbins Hikma said it had reduced the cash portion of the offer as Boehringer Ingelheim’s generic drugs business in the U.S. had lower-than-expected sales.